A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

Trial Profile

A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tofacitinib (Primary) ; Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ORAL STRATEGY
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jul 2017 Primary end point (Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response- Tofacitinib BID vs Tofacitinib BID + methotrexate) has not been met as per the results presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 06 Jul 2017 Results published in the The Lancet.
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top